Public Market Investing in Cancer Immunotherapy

Mentor Capital targets to efficiently raise approximately $125 Million in steps for operating entities like those in the Cancer Immunotherapy Index and invest in those or related companies via stock purchase or acquisition.

Mentor Capital started with few shares and stepped warrants at $0.65,  $1, $3, & $7 per share.  The shares are callable when the shares are $1 per share in the money, and must be exercised within 30 - 90 days as management best determines or they will be redeemed and passed to designees to exercise.  In this fashion, it is more highly certain than the normal case that significant warrant proceeds, now structured to equal $125 Million, will be eventually received by the Company.

The funds are now being invested into stock of Cancer Immunotherapy Index companies often to support FDA trial costs.  As time goes on, Mentor Capital stands ready to provide acquisition financing, liquidity for portfolio company shareholders, provide public shares and cash for cancer related acquisitions, and to continue to fund portfolio company corporate growth.

Because the Mentor portfolio companies represent substantial business with significant public market interest, Mentor Capital is working to  prepare for self-registration and to move off of the Pink Sheets which may allow for more robust trading in the stock.